GALR2 has potential as a therapeutic target in treating insulin resistance, as its activation alleviates insulin resistance through the P38MAPK/PGC-1α/GLUT4 and AKT/AS160/GLUT4 pathways in mouse skeletal muscle. The gene discussed is SLC2A4; the disease is Insulin resistance.